Literature DB >> 35107991

Epigenetic Mechanisms of Neural Plasticity in Chronic Neuropathic Pain.

Krishna Ghosh1, Hui-Lin Pan1.   

Abstract

Neuropathic pain is a challenging clinical problem and remains difficult to treat. Altered gene expression in peripheral sensory nerves and neurons due to nerve injury is well documented and contributes critically to the synaptic plasticity in the spinal cord and the initiation and maintenance of chronic pain. However, our understanding of the epigenetic mechanisms regulating the transcription of pro-nociceptive (e.g., NMDA receptors and α2δ-1) and antinociceptive (e.g., potassium channels and opioid and cannabinoid receptors) genes are still limited. In this review, we summarize recent studies determining the roles of histone modifications (including methylation, acetylation, and ubiquitination), DNA methylation, and noncoding RNAs in neuropathic pain development. We review the epigenetic writer, reader, and eraser proteins that participate in the transcriptional control of the expression of key ion channels and neurotransmitter receptors in the dorsal root ganglion after traumatic nerve injury, which is commonly used as a preclinical model of neuropathic pain. A better understanding of epigenetic reprogramming involved in the transition from acute to chronic pain could lead to the development of new treatments for neuropathic pain.

Entities:  

Keywords:  Chromatin; DRG neuron; G9a; NMDA receptor; epigenetics; neuron-restrictive silencer factor; nociceptor; potassium channel; spinal cord

Mesh:

Year:  2022        PMID: 35107991     DOI: 10.1021/acschemneuro.1c00841

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  4 in total

1.  5-Oxopyrrolidine-3-carboxamides as Nav1.8 Inhibitors for Treating Pain Disorders, Cough Disorders, and Acute and Chronic Itch Disorders.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-04-14       Impact factor: 4.345

2.  2-Oxooxazolidine-5-carboxamides as Nav1.8 Inhibitors for Treating Pain Disorders, Cough Disorders, and Acute and Chronic Itch Disorders.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-03-01       Impact factor: 4.345

3.  Virtual Special Issue: Epigenetics 2022.

Authors:  Courtney C Aldrich; Félix Calderón; Stuart J Conway; Chuan He; Jacob M Hooker; Donna M Huryn; Craig W Lindsley; Dennis C Liotta; Christa E Müller
Journal:  ACS Pharmacol Transl Sci       Date:  2022-09-09

4.  Virtual Special Issue: Epigenetics 2022.

Authors:  Courtney C Aldrich; Félix Calderón; Stuart J Conway; Chuan He; Jacob M Hooker; Donna M Huryn; Craig W Lindsley; Dennis C Liotta; Christa E Müller
Journal:  ACS Med Chem Lett       Date:  2022-10-13       Impact factor: 4.632

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.